Citations (87)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Prasad Sanjay Dhiwar, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, Ekta Singh, Abhishek Ghara, Lalmohan Maji, Sindhuja Sengupta & Ganesh Andhale. (2023) An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-18.
Read now
Read now
Rossella Martinello, Andrea Milani, Elena Geuna, Giorgia Zucchini, Caterina Aversa, Annamaria Nuzzo & Filippo Montemurro. (2016) Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer. Expert Opinion on Investigational Drugs 25:4, pages 393-403.
Read now
Read now
Filippo Montemurro, Valentina Rossi, Elena Geuna, Giorgio Valabrega, Rossella Martinello, Andrea Milani & Massimo Aglietta. (2012) Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. Expert Opinion on Pharmacotherapy 13:15, pages 2143-2156.
Read now
Read now
Howard A Burris$suffix/text()$suffix/text(). (2011) Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opinion on Biological Therapy 11:6, pages 807-819.
Read now
Read now
Elena Geuna, Andrea Milani, Stefania Redana, Valentina Rossi, Giorgio Valabrega, Massimo Aglietta & Filippo Montemurro. (2011) Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. Expert Opinion on Pharmacotherapy 12:4, pages 549-565.
Read now
Read now
Alexandre Bozec, Frédéric Peyrade, Jean-Louis Fischel & Gérard Milano. (2009) Emerging molecular targeted therapies in the treatment of head and neck cancer. Expert Opinion on Emerging Drugs 14:2, pages 299-310.
Read now
Read now
Jens Büntzel & Oliver Micke. (2009) Second-line chemotherapy in head and neck cancer: what should we expect?. Expert Review of Anticancer Therapy 9:3, pages 269-273.
Read now
Read now
Judith Loeffler-Ragg, Ilona Schwentner, Georg M Sprinzl & Heinz Zwierzina. (2008) EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opinion on Investigational Drugs 17:10, pages 1517-1531.
Read now
Read now
Antony W. Burgess. (2008) EGFR family: Structure physiology signalling and therapeutic targets†. Growth Factors 26:5, pages 263-274.
Read now
Read now
Filippo Montemurro, Stefania Redana, Giorgio Valabrega & Massimo Aglietta. (2007) Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference. Expert Opinion on Pharmacotherapy 8:8, pages 1179-1188.
Read now
Read now
Articles from other publishers (77)
Mohammed Helmy Faris Shalayel, Ghassab M. Al-Mazaideh, Abdulkareem A. Alanezi, Afaf F. Almuqati & Meshal Alotaibi. (2023) Diosgenin and Monohydroxy Spirostanol from Prunus amygdalus var amara Seeds as Potential Suppressors of EGFR and HER2 Tyrosine Kinases: A Computational Approach. Pharmaceuticals 16:5, pages 704.
Crossref
Crossref
Justine Galambus & Kenneth Y. Tsai. (2022) Molecular and immune targets in cutaneous squamous cell carcinoma. Molecular Carcinogenesis 62:1, pages 38-51.
Crossref
Crossref
Matilda Xinwei Lee, Andrea L. A. Wong, Samuel Ow, Raghav Sundar, David S. P. Tan, Ross A. Soo, Cheng Ean Chee, Joline S. J. Lim, Wei Peng Yong, Siew Eng Lim, Boon Cher Goh, Lingzhi Wang & Soo Chin Lee. (2022) Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors. Targeted Oncology 17:2, pages 141-151.
Crossref
Crossref
Ana I. Álvarez-Mercado, Albert Caballeria-Casals, Carlos Rojano-Alfonso, Jesús Chávez-Reyes, Marc Micó-Carnero, Alfredo Sanchez-Gonzalez, Araní Casillas-Ramírez, Jordi Gracia-Sancho & Carmen Peralta. (2021) Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection. Biomedicines 9:9, pages 1158.
Crossref
Crossref
Julia Chen, Maree Colosimo & Elgene Lim. (2021) The management of HER2‐positive early breast cancer: Current and future therapies. Asia-Pacific Journal of Clinical Oncology 17:S6, pages 3-12.
Crossref
Crossref
Haswanth Vundavilli, Aniruddha Datta, Chao Sima, Jianping Hua, Rosana Lopes & Michael Bittner. (2021) Targeting oncogenic mutations in colorectal cancer using cryptotanshinone. PLOS ONE 16:2, pages e0247190.
Crossref
Crossref
Conrad V. Simoben, Fidele Ntie-Kang, Dina Robaa & Wolfgang Sippl. (2020) Case studies on computer-based identification of natural products as lead molecules. Physical Sciences Reviews 5:10.
Crossref
Crossref
Asadollahi Parisa, Ghanavati Roya, Rohani Mahdi, Razavi Shabnam, Esghaei Maryam & Talebi Malihe. (2020) Anti-cancer effects of Bifidobacterium species in colon cancer cells and a mouse model of carcinogenesis. PLOS ONE 15:5, pages e0232930.
Crossref
Crossref
Eduardo Noriega-Iribe, Laura Díaz-Rubio, Arturo Estolano-Cobián, Victor Wagner Barajas-Carrillo, José M. Padrón, Ricardo Salazar-Aranda, Raúl Díaz-Molina, Victor García-González, Rocio Alejandra Chávez-Santoscoy, Daniel Chávez & Iván Córdova-Guerrero. (2020) In Vitro and In Silico Screening of 2,4,5-Trisubstituted Imidazole Derivatives as Potential Xanthine Oxidase and Acetylcholinesterase Inhibitors, Antioxidant, and Antiproliferative Agents. Applied Sciences 10:8, pages 2889.
Crossref
Crossref
Priyanka Verma, Pooja Mittal, Archana Singh & Indrakant K. Singh. (2020) New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight. Anti-Cancer Agents in Medicinal Chemistry 19:18, pages 2156-2176.
Crossref
Crossref
Chaokun Wang, Jing Chen, Xiangyun Xu, Xiaochen Hu, Dejiu Kong, Gaofeng Liang & Xinshuai Wang. (2020) Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review. Technology in Cancer Research & Treatment 19, pages 153303382096072.
Crossref
Crossref
Nicoletta Urbano, Manuel Scimeca, Rita Bonfiglio, Elena Bonanno & Orazio Schillaci. (2019) New advance in breast cancer pathology and imaging. Future Oncology 15:23, pages 2707-2722.
Crossref
Crossref
Manuel Scimeca, Nicoletta Urbano, Rita Bonfiglio, Andrea Duggento, Nicola Toschi, Orazio Schillaci & Elena Bonanno. (2019) Novel insights into breast cancer progression and metastasis: A multidisciplinary opportunity to transition from biology to clinical oncology. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1872:1, pages 138-148.
Crossref
Crossref
Thingreila Muinao, Hari Prasanna Deka Boruah & Mintu Pal. 2019. Polysaccharide Carriers for Drug Delivery. Polysaccharide Carriers for Drug Delivery
413
441
.
Ayako Nakashoji, Tetsu Hayashida, Takamichi Yokoe, Hinako Maeda, Tomoka Toyota, Masayuki Kikuchi, Rurina Watanuki, Aiko Nagayama, Tomoko Seki, Maiko Takahashi, Takayuki Abe & Yuko Kitagawa. (2018) The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer. Cancer Treatment Reviews 62, pages 9-17.
Crossref
Crossref
Soheila Korourian. 2018. The Breast. The Breast
145
155.e4
.
Afsane Bahrami, Majid Khazaei, Soodabeh Shahidsales, Seyed Mahdi Hassanian, Malihe Hasanzadeh, Mina Maftouh, Gordon A. Ferns & Amir Avan. (2017) The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress. Journal of Cellular Biochemistry 119:1, pages 213-222.
Crossref
Crossref
Reza Nedaeinia, Amir Avan, Mehdi Ahmadian, Sasan Nedaee Nia, Maryam Ranjbar, Mohammadreza Sharifi, Mohammad Goli, Ahmad Piroozmand, Esmail Nourmohammadi, Mostafa Manian, Gordon A. Ferns, Majid Ghayour‐Mobarhan & Rasoul Salehi. (2017) Current Status and Perspectives Regarding LNA‐Anti‐miR Oligonucleotides and microRNA miR‐21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer. Journal of Cellular Biochemistry 118:12, pages 4129-4140.
Crossref
Crossref
Tushar Piyush, Anisha R Chacko, Paulina Sindrewicz, John Hilkens, Jonathan M Rhodes & Lu-Gang Yu. (2017) Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells. Cell Death & Differentiation 24:11, pages 1937-1947.
Crossref
Crossref
Renan B. Ferreira, Mengxiong Wang, Mary E. Law, Bradley J. Davis, Ashton N. Bartley, Paul J. Higgins, Michael S. Kilberg, Katherine E. Santostefano, Naohiro Terada, Coy D. Heldermon, Ronald K. Castellano & Brian K. Law. (2017) Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. Oncotarget 8:17, pages 28971-28989.
Crossref
Crossref
Stefan Glück. (2017) Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer. Clinical Breast Cancer 17:2, pages 79-90.
Crossref
Crossref
Yaling Zhang, Ying Zhang, Juan Liu, Li Chen, Lijun Zhao, Baolin Li & Wei Wang. (2017) Synthesis and in vitro biological evaluation of novel quinazoline derivatives. Bioorganic & Medicinal Chemistry Letters 27:7, pages 1584-1587.
Crossref
Crossref
Jiyeon HyeonSoo Youn ChoMin Eui HongSo Young KangIngu DoYoung Hyuck ImEun Yoon Cho. (2017)
NanoString nCounter® Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction,
In Situ
Hybridization, and Immunohistochemistry
. Journal of Breast Cancer 20:3, pages 286.
Crossref
Crossref
Alexandru Filippi, Oana-Alina Ciolac, Constanța Ganea & Maria-Magdalena Mocanu. (2017) ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases. Journal of Oncology 2017, pages 1-20.
Crossref
Crossref
Marta Hergueta-Redondo, David Sarrio, Ángela Molina-Crespo, Rocío Vicario, Cristina Bernadó-Morales, Lidia Martínez, Alejandro Rojo-Sebastián, Jordi Serra-Musach, Alba Mota, Ángel Martínez-Ramírez, Maria Ángeles Castilla, Antonio González-Martin, Sonia Pernas, Amparo Cano, Javier Cortes, Paolo G. Nuciforo, Vicente Peg, José Palacios, Miguel Ángel Pujana, Joaquín Arribas & Gema Moreno-Bueno. (2016) Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget 7:35, pages 56295-56308.
Crossref
Crossref
Wentong Li, Limin Zhai, Hui Wang, Chuanliang Liu, Jinbao Zhang, Weijuan Chen & Qun Wei. (2016) Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget 7:19, pages 27778-27786.
Crossref
Crossref
Xiufang Cheng, Huamin Wang, Fuhong Xiao & Guo-Jun Deng. (2016) Lewis acid-catalyzed 2-arylquinazoline formation from N′-arylbenzimidamides and paraformaldehyde. Green Chemistry 18:21, pages 5773-5776.
Crossref
Crossref
Frederik Marmé. 2016. Management of Breast Diseases. Management of Breast Diseases
335
390
.
Vajihe Akbari, Hamid Mir Mohammad Sadeghi, Abbas Jafarian-Dehkordi, Daryoush Abedi & C. Perry Chou. (2015) Improved biological activity of a single chain antibody fragment against human epidermal growth factor receptor 2 (HER2) expressed in the periplasm of Escherichia coli. Protein Expression and Purification 116, pages 66-74.
Crossref
Crossref
Sun-Young Jang, Seul Lee, Mira Kim, Young Jin Ham, Mi Young Cha, Kwee Hyun Suh, Young Hoon Kim, Ara Kwon, Hae Ju Kang, Kyung Hoon Min & Kwang-Ok Lee. (2015) Synthesis of Quinazoline Analogues with Differential Activity for HER2-overexpressing Breast Cancer Cells. Bulletin of the Korean Chemical Society 36:7, pages 1933-1935.
Crossref
Crossref
Shahid Ahmed, Amer Sami & Jim Xiang. (2015) HER2-directed therapy: current treatment options for HER2-positive breast cancer. Breast Cancer 22:2, pages 101-116.
Crossref
Crossref
Antonia Bellizzi, Maria Greco, Rosa Rubino, Angelo Paradiso, Stefania Forciniti, Katrine Zeeberg, Rosa Cardone & Stephan Reshkin. (2014) The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells. International Journal of Oncology.
Crossref
Crossref
Edward L Nelson. (2014) HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations. Clinical Investigation 4:9, pages 791-823.
Crossref
Crossref
Xusheng Bai, Enke Zhang, Hua Ye, Vijayalakshmi Nandakumar, Zhuo Wang, Lihong Chen, Chuanning Tang, Jianhui Li, Huijin Li, Wei Zhang, Wei Han, Feng Lou, Dandan Zhang, Hong Sun, Haichao Dong, Guangchun Zhang, Zhiyuan Liu, Zhishou Dong, Baishuai Guo, He Yan, Chaowei Yan, Lu Wang, Ziyi Su, Yangyang Li, Lindsey Jones, Xue F. Huang, Si-Yi Chen & Jinglong Gao. (2014) PIK3CA and TP53 Gene Mutations in Human Breast Cancer Tumors Frequently Detected by Ion Torrent DNA Sequencing. PLoS ONE 9:6, pages e99306.
Crossref
Crossref
WEIWEI QI, XIAOXIAO LI, YONGCHUN ZHANG, RUYONG YAO, WENSHENG QIU, DONGFANG TANG & JUN LIANG. (2014) Overexpression of Her-2 upregulates FoxM1 in gastric cancer. International Journal of Molecular Medicine 33:6, pages 1531-1538.
Crossref
Crossref
Filippo Montemurro & Maurizio Scaltriti. (2014) Biomarkers of drugs targeting HER-family signalling in cancer. The Journal of Pathology 232:2, pages 219-229.
Crossref
Crossref
Siyuan Zhang & Dihua Yu. 2015. Molecular Oncology. Molecular Oncology
843
853
.
Paramita Ghosh, Yun Qiu, Ling-Yu Wang & Hsing-Jien Kung. 2015. Molecular Oncology. Molecular Oncology
58
75
.
Jason A Incorvati, Shilpan Shah, Ying Mu & Janice Lu. (2013) Targeted therapy for HER2 positive breast cancer. Journal of Hematology & Oncology 6:1.
Crossref
Crossref
Marawan Ahmed, Maiada M. Sadek, Khaled A. Abouzid & Feng Wang. (2013) In silico design: Extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2. Journal of Molecular Graphics and Modelling 44, pages 220-231.
Crossref
Crossref
KE-KANG SUN, YANG YANG, LIN ZHAO, LI-LI WANG & YANG JIAO. (2013) Transducer of erbB2.1 is a potential cellular target of gefitinib in lung cancer therapy. Oncology Letters 5:1, pages 373-377.
Crossref
Crossref
Inken Wierstra. 2013.
191
419
.
M. Kaufmann, G. von Minckwitz, A. Scharl, S. D. Costa & M. Linder. 2013. Die Gynäkologie. Die Gynäkologie
625
705
.
Lulu Wang, Qian Liu, Hong Zhao, Kemi Cui, Linli Yao, Fang Nie, Guangxu Jin, Aijun Hao & Stephen T.C. Wong. (2012) Differential effects of low‐ and high‐dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion. Journal of Neuroscience Research 91:1, pages 128-137.
Crossref
Crossref
Mehmet Ali Nahit Sendur, Sercan Aksoy, Nuriye Yildirim Ozdemir, Nurullah Zengin & Kadri Altundag. (2012) What is the Mechanism of Progression with Trastuzumab Treatment - Escape or Resistance?. Asian Pacific Journal of Cancer Prevention 13:11, pages 5915-5916.
Crossref
Crossref
M. Fralick, J.F. Hilton, N. Bouganim, M. Clemons & E. Amir. (2012) Dual Blockade of HER2 — Twice as Good or Twice as Toxic?. Clinical Oncology 24:9, pages 593-603.
Crossref
Crossref
C T Karadedou, A R Gomes, J Chen, M Petkovic, K-K Ho, A K Zwolinska, A Feltes, S Y Wong, K Y K Chan, Y-N Cheung, J W H Tsang, J J Brosens, U-S Khoo & E W-F Lam. (2011) FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene 31:14, pages 1845-1858.
Crossref
Crossref
Carina Neto, C?lia Fernandes, Maria Cristina Oliveira, Lurdes Gano, Filipa Mendes, Torsten Kniess & Isabel Santos. (2012) Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents. Nuclear Medicine and Biology 39:2, pages 247-260.
Crossref
Crossref
Fengjuan Fan, Alexander Schimming, Dirk Jaeger & Klaus Podar. (2012) Targeting the Tumor Microenvironment: Focus on Angiogenesis. Journal of Oncology 2012, pages 1-16.
Crossref
Crossref
Keith D. Hunter & Robert Bolt. 2012. Biotargets of Cancer in Current Clinical Practice. Biotargets of Cancer in Current Clinical Practice
19
59
.
Giorgio Valabrega, Sonia Capellero, Giuliana Cavalloni, Gianluca Zaccarello, Annalisa Petrelli, Giorgia Migliardi, Andrea Milani, Caterina Peraldo-Neia, Loretta Gammaitoni, Anna Sapino, Carla Pecchioni, Aldo Moggio, Silvia Giordano, Massimo Aglietta & Filippo Montemurro. (2010) HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Research and Treatment 130:1, pages 29-40.
Crossref
Crossref
Zana K. Ahmad, Carrie M. Brown, Roberto A. Cueva, Allen F. Ryan & Joni K. Doherty. (2011) ErbB Expression, Activation, and Inhibition With Lapatinib and Tyrphostin (AG825) in Human Vestibular Schwannomas. Otology & Neurotology 32:5, pages 841-847.
Crossref
Crossref
. 2011. Growth Factors and Their Receptors in Cell Differentiation, Cancer and Cancer Therapy. Growth Factors and Their Receptors in Cell Differentiation, Cancer and Cancer Therapy
249
347
.
S. Ammoun, C. H. Cunliffe, J. C. Allen, L. Chiriboga, F. G. Giancotti, D. Zagzag, C. O. Hanemann & M. A. Karajannis. (2010) ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro-Oncology 12:8, pages 834-843.
Crossref
Crossref
Cimona V. Hinton, Shalom Avraham & Hava Karsenty Avraham. (2008) Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clinical & Experimental Metastasis 27:2, pages 97-105.
Crossref
Crossref
Tanja Schneider-Merck & Martin Trepel. 2010. Small Molecules in Oncology. Small Molecules in Oncology
45
59
.
Mattea Linder & Gunter von Minckwitz. 2010. Management of Breast Diseases. Management of Breast Diseases
353
372
.
Francine Walker, Laurent Abramowitz, Dalila Benabderrahmane, Xavier Duval, Véronique Descatoire, Dominique Hénin, Thérèse Lehy & Thomas Aparicio. (2009) Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Human Pathology 40:11, pages 1517-1527.
Crossref
Crossref
James E. Frampton. (2009) Lapatinib. Drugs 69:15, pages 2125-2148.
Crossref
Crossref
Hongyu Zhao & Zongru Guo. (2009) Medicinal chemistry strategies in follow-on drug discovery. Drug Discovery Today 14:9-10, pages 516-522.
Crossref
Crossref
M. E. Lacouture, S. M. Laabs, M. Koehler, R. W. Sweetman, A. J. Preston, A. Di Leo, H. L. Gomez, V. M. Salazar, J. A. Byrne, K. M. Koch & K. L. Blackwell. (2008) Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Research and Treatment 114:3, pages 485-493.
Crossref
Crossref
Ursula B. McGovern, Richard E. Francis, Barrie Peck, Stephanie K. Guest, Jun Wang, Stephen S. Myatt, Janna Krol, Jimmy M-M. Kwok, Andreas Polychronis, R. Charles Coombes & Eric W-F. Lam. (2009) Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Molecular Cancer Therapeutics 8:3, pages 582-591.
Crossref
Crossref
Sarah Morgan & Jennifer R. Grandis. (2009) ErbB receptors in the biology and pathology of the aerodigestive tract. Experimental Cell Research 315:4, pages 572-582.
Crossref
Crossref
E. Montagna, G. Cancello, D. D’Agostino, R. Lauria, V. Forestieri, A. Esposito, L. Silvestro, A. Accurso, S. De Placido & M. De Laurentiis. (2008) Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. Cancer Chemotherapy and Pharmacology 63:2, pages 275-280.
Crossref
Crossref
Amy J Jackson-Fisher, Gary Bellinger, Jerrica L Breindel, Fatteneh A Tavassoli, Carmen J Booth, James K Duong & David F Stern. (2008) ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Research 10:6.
Crossref
Crossref
Filippo Montemurro, Stefania Redana, Franco Nolè, Michela Donadio, Maria Elena Jacomuzzzi, Giorgio Valabrega, Giuseppe Viale, Anna Sapino & Massimo Aglietta. (2008) Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. BMC Cancer 8:1.
Crossref
Crossref
Filippo Montemurro, Stefania Redana, Giuseppe Viale, Giuseppina Sanna, Michela Donadio, Giorgio Valabrega, Barbara del Curto, Alberto Bottini, Gerardo Botti, Angelo Paolo dei Tos, Maria Elena Jacomuzzi, Maurizio Di Bonito, Saverio Danese, Matteo Clavarezza, Janina Kulka, Silvana Di Palma, Antonio Durando, Anna Sapino & Massimo Aglietta. (2008) Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. Clinical Breast Cancer 8:5, pages 436-442.
Crossref
Crossref
Julia Y Ljubimova, Manabu Fujita, Alexander V Ljubimov, Vladimir P Torchilin, Keith L Black & Eggehard Holler. (2008) Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine 3:2, pages 247-265.
Crossref
Crossref
Alphonse E Sirica. (2008) Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World Journal of Gastroenterology 14:46, pages 7033.
Crossref
Crossref
Shridhar Hegde & Michelle Schmidt. 2008.
455
497
.
Weibo Cai, Gang Niu & Xiaoyuan Chen. (2007) Multimodality imaging of the HER-kinase axis in cancer. European Journal of Nuclear Medicine and Molecular Imaging 35:1, pages 186-208.
Crossref
Crossref
Julia Y. Ljubimova, Keith L. Black, Alexander V. Ljubimov & Eggehard Holler. 2008. Multifunctional Pharmaceutical Nanocarriers. Multifunctional Pharmaceutical Nanocarriers
233
262
.
Janna Krol, Richard E. Francis, André Albergaria, Andrew Sunters, Andreas Polychronis, R. Charles Coombes & Eric W.-F. Lam. (2007) The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Molecular Cancer Therapeutics 6:12, pages 3169-3179.
Crossref
Crossref
Xiaoyun Cheng & Mien-Chie Hung. (2007) Breast cancer brain metastases. Cancer and Metastasis Reviews 26:3-4, pages 635-643.
Crossref
Crossref
Cristina Grávalos, Javier Cassinello, Isabel Fernández-Rañada & Esther Holgado. (2007) Role of Tyrosine Kinase Inhibitors in the Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer 6:10, pages 691-699.
Crossref
Crossref
P Vallance & M Levick. (2007) Drug Discovery and Development in the Age of Molecular Medicine. Clinical Pharmacology & Therapeutics 82:4, pages 363-366.
Crossref
Crossref
Sohita Dhillon & Antona J Wagstaff. (2007) Lapatinib. Drugs 67:14, pages 2101-2108.
Crossref
Crossref